(Total Views: 511)
Posted On: 12/09/2024 5:21:03 PM
Post# of 148870
From Chat GPT
In March 2022, Scott Kelly says:
"We have been in contact in London with the university and foundation to further evaluate the potential of LL as a treatment in Alzheimer's. Their interest is in the role of neuro inflammation. It is similar to the role of cancer where initially people did not believe that cancer had an inflammatory component. I think the same is true in a number of central nervous system disorders."
Dr. Paul Edison was on CytoDyn's Scientific Board of Advisors May 2022 , right around the time Kelly made that comment.
Now, Dr. Lalezari says an anonymous Foundation shall be funding CytoDyn's Alzheimer's Trial.
CytoDyn is pursuing two other clinical studies linked to inflammation. First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease. The study will evaluate a neuroradiology primary endpoint to determine efficacy. We are also grateful to the foundation that has tentatively agreed to fund this study but wishes to remain anonymous at this time.
Quote:
"Dr. Paul Edison, a prominent researcher in the field of Alzheimer's disease, was indeed one of the two-time grant recipients of the Part the Cloud + Bill Gates Partnership (2020 Challenge).
Dr. Edison, a professor of Translational Neuroimaging at Imperial College London, received funding through the initiative to support his groundbreaking work in Alzheimer's disease. His research focuses on the use of imaging techniques to identify and target new biomarkers for Alzheimer's , aiming to improve the understanding of the disease and its progression. By advancing non-invasive imaging technology, Dr. Edison’s research could potentially revolutionize how we diagnose and treat Alzheimer's in its early stages.
The Part the Cloud initiative, supported by Bill Gates and the Alzheimer's Drug Discovery Foundation (ADDF), was designed to speed up the development of novel therapies, and Dr. Edison’s innovative research has been a key part of this mission. "
In March 2022, Scott Kelly says:
"We have been in contact in London with the university and foundation to further evaluate the potential of LL as a treatment in Alzheimer's. Their interest is in the role of neuro inflammation. It is similar to the role of cancer where initially people did not believe that cancer had an inflammatory component. I think the same is true in a number of central nervous system disorders."
Dr. Paul Edison was on CytoDyn's Scientific Board of Advisors May 2022 , right around the time Kelly made that comment.
Now, Dr. Lalezari says an anonymous Foundation shall be funding CytoDyn's Alzheimer's Trial.
CytoDyn is pursuing two other clinical studies linked to inflammation. First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease. The study will evaluate a neuroradiology primary endpoint to determine efficacy. We are also grateful to the foundation that has tentatively agreed to fund this study but wishes to remain anonymous at this time.
(14)
(0)Scroll down for more posts ▼
